The Calamos S&P 500® Structured Alt Protection ETF®– March (CPSR) has announced an upside cap rate of 7.63% over its one-year outcome period following its launch on March 3, 2025. The Calamos Nasdaq-100® Structured Alt Protection ETF® — March (CPNM) has announced an upside cap rate of 8….

Twenty-four-week data from the Ph1/2a trial in glaucoma patients reveals PER-001 to be well-tolerated. Proof of concept is established with both strong functional and structural outcomes Glaucoma patients treated with PER-001 on top of IOP reducing therapies experienced a mean improvement…

Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.